Implementing methods in the ELEGANCE registry to increase diversity in clinical research.
Eric A Secemsky, Jay Giri, Marianne Brodmann...
https://pubmed.ncbi.nlm.nih.gov/37742734/Actively Recruiting
Led by Boston Scientific Corporation · Updated on 2026-10-16
5000
Participants Needed
86
Research Sites
N/A
Total Duration
This research aims to collect real-world information about the treatment of lesions in the peripheral vasculature, focusing on patients who may not have been included in previous Peripheral Vascular Disease PVD studies. It evaluates the use of commercially available drug-eluting devices made by Boston Scientific Corporation to better understand their application and health economic impact globally. Participants in this registry receive treatment with Boston Scientific drug-eluting devices such as the Ranger14 Paclitaxel-Coated PTA Balloon Catheter and the ELUVIA14 Drug-Eluting Vascular Stent System. The study is observational and includes patients from multiple countries, with follow-up lasting up to 2 years in most countries and up to 5 years in China. Some participants at select sites will also complete additional assessments like quality of life questionnaires, six-minute walk tests, and healthcare utilization data collection. Throughout the study, participants undergo assessments based on standard care procedures. Researchers will monitor major adverse events and lesion patency at 12 months. Data collected includes health economics and patient outcomes to support the safe use of these devices. The total study duration extends up to 5 years depending on location, with scheduled follow-ups to gather ongoing information about treatment effects and patient health.
CONDITIONS
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Y
Yumna Akhtar, MS
K
Kara Johnson
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boston Scientific Corporation
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years in most countries and up to 5 years in China
Participants receive treatment with Boston Scientific drug-eluting devices and are followed up according to standard care. Some participants at select sites complete additional assessments like quality of life questionnaires and six-minute walk tests.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Eric A Secemsky, Jay Giri, Marianne Brodmann...
https://pubmed.ncbi.nlm.nih.gov/37742734/Boston Scientific Corporation
Lead Sponsor